Thromboembolism in Patients with Prosthetic Heart Valves. An Adequatety Controlled Intense Anticoagulant Therapy and its Influence on the Occurrence of Thromboembolism in Relation to Valve Type

Authors:
  • HGH. Gössinger
    H. Gössinger
  • HNH. Niessner
    H. Niessner
  • BGB. Grubeck
    B. Grubeck
  • HMH. Mösslacher
    H. Mösslacher
  • PBP. Bettelheim
    P. Bettelheim
  • KLK. Lechner
    K. Lechner
  • JMJ. Mlczoch
    J. Mlczoch
  • EDE. Domanig
    E. Domanig

Abstract
This study was designed to evaluate the efficacy of carefully controlled treatment with oral anticoagulants in patients with different mechanical heart valve prostheses. One hundred eighty-one patients with various types of prosthetic valves (mitral 89, aortic 87, combined 5) received oral anticoagulation aiming at Thrombotest (TT) values between 5 % and 12 %. Median follow-up was 46 months; 80.8 % of all TT determinations were below 12 %. The thromboembolic rate was 0.25 %/year in patients with aortic valve replacement (AVR) and 4.87 %/year in patients with mitral valve replacement (MVR). There was a strikingly lower incidence of thromboembolism with newer types of valves (Björk-Shiley convex-concave) in the mitral position under exactly the same intensity and stability of anticoagulant treatment. Clinically overt valve occlusion could be almost completely prevented (0.12 %/year) in prostheses at both sites. Severe hemorrhage occurred at a rate of 1.71 %/year and fatal bleeding at a rate of 0.37 %/year. Our results indicate that carefully controlled anticoagulation is effective in the reduction of thromboembolic complications at a reasonable risk of bleeding.